Myeloproliferative Neoplasms News

ASCO will recognize several researchers and scientists during the society’s annual meeting, scheduled for June 3-7 in Chicago.

Although Medicare expenditures varied among older patients with myelodysplastic syndromes, higher costs did not appear correlated with improved survival outcomes, according to the results of an observational study.

Steven T. Rosen, MD, director of the Comprehensive Cancer Center and Beckman Research Institute, City of Hope, Duarte, Calif., reviews the range of immune approaches hematologists have at their disposal today and the practice implications of these treatment options.

At the December ASH Annual Meeting and Exposition, there were many exciting abstracts in myeloproliferative neoplasms, particularly in myelofibrosis. We are seeing advances in science, as well as in prognosis and clinical care, that are energizing the field.

Light consumption of alcohol among nonsmokers may decrease the risk for myelodysplastic syndrome compared with abstaining from alcohol, according to results of a case–control study.

HemOnc Today presents this guide to drugs in phase 2 or phase 3 development for myeloproliferative neoplasms and myelodysplastic syndrome. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice.

Clifford A. Hudis, MD, FACP, has been named the next CEO of ASCO.

Rigosertib failed to significantly prolong OS compared with best supportive care in patients with myelodysplastic syndromes who had experienced hypomethylating drug treatment failure, according to the results of an open-label, randomized phase 3 trial.

Despite considerable advancements made in cancer treatment — such as with precision medicine, genomic profiling and immunotherapies — persistent financial, coverage and delivery issues threaten patients’ access to these modalities, according to ASCO’s “State of Cancer Care in America: 2016” report.

Patients who underwent radiotherapy during treatment for prostate cancer demonstrated a greater risk for second malignancies than those who did not receive radiotherapy, according to results of a systematic review and meta-analysis.